Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
Delcath Systems announced two investigator-initiated trials-in-progress abstracts to be presented at the 2026 ASCO Annual Meeting in Chicago. The first abstract (TPS9605) describes a Phase 2 trial evaluating sequential treatment with HEPZATO followed by tebentafusp in metastatic uveal melanoma with liver metastases. The study opened for enrollment in November 2025. The second abstract (TPS9600) outlines a Phase 1b/2 study combining HEPZATO with nivolumab and relatlimab as a first-line treatment for metastatic non-uveal melanoma with liver involvement.
Key figures
- Drug Name
- HEPZATO KIT (melphalan)
- Phase Of Trial
- Phase 2 (uveal melanoma), Phase 1b/2 (non-uveal melanoma)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.